https://www.selleckchem.com/products/fin56.html
These options include somatostatin analogues, everolimus, peptide receptor radionuclide therapy, chemotherapy, radiotherapy, antiangiogenic agents, and immunotherapy. In this article, we provide a comprehensive review about the molecular and genetic background of BCs, and about the treatment of local and metastatic disease, as well as the main paraneoplastic syndromes that have been associated with this tumor. The increase of lymphoma patient survival led to a modification of the incidence of long-term sequelae, including second malignanc
Aimer
Commentaire
Partagez
